Selective Alterations of Opiate Receptor Subtypes in Mono sodium Glutamate-Treated Rats by Young, Elizabeth A. et al.
Juurnul of Neurochemistry 
Raven Press, New York 
@ 1983 International Society for Neurochemistry 
0022-3042183/0601- 1558/$03.50/0 
Selective Alterations of Opiate Receptor Subtypes in 
Monosodium Glutamate-Treated Rats 
Elizabeth Young, *John Olney, and Huda Akil 
Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan, and *Department of Psychiatry, 
Wushington University, S t .  Louis, Missouri, U . S . A .  
Abstract: Neonatal treatment of rats with monosodium 
glutamate (MSG) has been demonstrated to destroy cell 
bodies of neurons in the arcuate nucleus including the 
brain beta-endorphin (B-END) system. The effects on 
opiate receptors of the loss of B-END is unknown. Neo- 
natal rats were treated with MSG as previously described. 
After reaching maturity (7-9 months), MSG-treated rats 
and litter-matched untreated control rats were decapitated 
and brains dissected into brain regions. Opiate receptor 
assays were run with [3H]morphine (mu receptor ligand) 
and [3H]~-alanine2-~-leucine5 (DADL) enkephalin (delta 
receptor ligand) for each brain region for both MSG and 
control rats simultaneously. Scatchard plot analyses 
showed a selective increase in delta receptors in the thala- 
mus only. No corresponding change in mu receptors in 
the thalamus was found. The cross-competition IC5,, data 
supported this conclusion, showing a loss in the potency 
Injection of monosodium glutamate (MSG) dur- 
ing the neonatal period produces destruction of cell 
bodies in the arcuate nucleus of the hypothalamus 
(Olney , 1969). Dopamine and acetylcholine trans- 
ferase levels are reduced in the arcuate nucleus 
after MSG treatment (Lechan et al., 1977; Nemeroff 
et al., 1977). Since the cell bodies of the brain beta- 
endorphin (B-END) system, which also contains 
adrenocorticotropic hormone (ACTH), are located 
within the arcuate nucleus (Watson et al., 1977; 
1978u, b) ,  one might expect a decrease in B-END in 
MSG-treated animals. Immunocytochemical tech- 
niques demonstrate a loss of the cell bodies and de- 
generation of the fibers from the ACTH/B-END 
system in brain after MSG treatment (Bodnar et al., 
1980). This destruction of the ACTH/B-END sys- 
tem has been confirmed by radioimmunoassay 
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of morphine in displacing ["HIDADL enkephalin in the 
thalamus of MSG-treated rats. This shift in delta recep- 
tors produced an IC50 displacement pattern in thalamus, 
ordinarily a mu-rich area, similar to that of striatum or 
cortex, delta-rich areas, again indicating an increase in 
delta receptors. Similar changes in delta receptors in other 
brain regions were not found. These results represent one 
of the few examples of a selective and localized shift in 
delta with no change in mu sites. Furthermore, the delta 
increase may reflect an up-regulation of the receptors in 
thalamus after chronic loss of the endogenous opioid 
B-END. Key Words: Multiple opiate receptors-Mono- 
sodium glutamate- Beta-endorphin-Opiate peptides. 
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(RIA) measurements of ACTH and B-END in the 
brain (Kreiger et al., 1979). MSG lesions have no ef- 
fect on pituitary ACTH or B-END content (Bodnar 
et al., 1980). 
B-END binds to opiate receptors with good affin- 
ity; whether it has its own unique subset of opiate 
receptors in brain remains to be determined (Law et 
al., 1979; Schulz et al., 1979; Akil et al., 1980). The 
destruction of the B-END fibers of the arcuate nu- 
cleus might be expected to have an effect on opiate 
receptors in the terminal regions of these arcuate 
fibers primarily in limbic structures. 
The existence of subtypes of opiate receptors was 
first postulated by Martin et al. (1976) on the basis 
of pharmacological and behavioral studies. The mu 
and delta subtypes seem to be the most easily de- 
monstrable in brain tissue preparation and binding 
a-MSH, Alpha-melanotropin stimulating hormone; B-END, 
Beta-endorphin; DADL, D-Alanine' ~-1eucine~; DMSO, Dimeth- 
ylsulfoxide; MSG, Monosodium glutamate; RIA, Radioimmuno- 
assay. 
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studies (Lord et al., 1977; Chang and Cuatrecasas, 
1979). The mu or alkaloid receptor preferentially 
binds morphine. The delta or peptide receptor pref- 
erentially binds enkephalins and is believed to be 
the receptor for methionine- and leucine-enkepha- 
lin. B-END binds well to both mu and delta recep- 
tors in in vijro binding preparations with a slight 
preference toward the mu sites. Whether B-END 
binds to mu or delta receptors or neither in vivo is 
unclear. 
There are a number of reasons to investigate the 
effect of various treatments on different opiate re- 
ceptor subtypes, particularly in specific brain sites. 
Although many biochemical studies support the ex- 
istence of multiple types in brain, little is known 
about the physiological significance of these sub- 
types or their unique perturbations by biological 
events. Furthermore, studies searching €or changes 
in opiate receptors during such treatment as chronic 
opiate administration have been disappointing. Pos- 
sibly, this is due to the fact that they measure multi- 
ple types of receptors in whole brain. Finally, the 
MSG model has been proposed as a good tool for 
depleting B-END in brain, leaving other endoge- 
nous opioids unaltered. Uncovering the specific 
changes in opiate binding accompanying this lesion 
should help further define the model and evaluate 
its usefulness for behavioral studies. 
One approach in investigating possible changes in 
opiate receptor subtypes is to look €or regional dif- 
ferences. Chang and Cuatrecasas (1979), using low 
concentrations of radiolabelled dihydromorphine 
and D-alanine2 ~-1eucine~ (DADL) enkephalin, re- 
ported differences in the distribution of mu and 
delta receptors among brain regions. In addition to 
the traditional Scatchard plot analyses for mu and 
delta receptor number in each brain region, we have 
utilized cross-competition experiments between li- 
gands to study IC,, values. In a sense, the various 
regions provide "multiple parallel assays" for com- 
paring populations of receptors. A useful index to 
regional differences is the ratio of IC,, values for a 
given brain area. Thus, 
IC,, of morphine vs. r3H1DADL enkephalin 
IC,,, of morphine vs. ["Hlmorphine 
varies dramatically across regions. In areas contain- 
ing almost pure mu receptors (i.e., [3HlDADL en- 
kephalin is actually labeling mu sites), the ratio ap- 
proaches 1. Conversely, in areas extremely rich in 
delta, PHIDADL enkephalin labels the latter sites 
and morphine is impotent against it, leading to high 
IC,,, values in the numerators, and ratios of 10-100. 
A final advantage of this approach is that it con- 
trols for nonspecific effects, such as differential 
breakdown in different areas. In the above para- 
digms of cross-competition, each brain area serves 
as its own control. This is particularly valuable 
when different groups of animals are being com- 
pared. 
MATERIALS AND METHODS 
Neonatal rats were treated with MSG according to a 
modified schedule of that previously described (Olney, 
1969). Two different strains of rats were used. Holtzman 
rats were obtained from Madison, WI, and treated with 
2 g MSGlkg weight on the first 2 postnatal days. Repeat 
treatment at 4 g MSGIkg was done 4,6, and 8 days postna- 
tally. Male MSG-treated rats and age- and sex-matched 
controls were killed at approximately 9 months of age. 
The second group of MSG-treated rats were Harlan rats 
from Indianapolis, IN, which received the same dose 
schedule treatment. Female MSG-lesioned rats and age- 
and sex-matched controls were decapitated at approxi- 
mately 7 months of age. After decapitation the brains 
were rapidly removed and dissected on ice into the fol- 
lowing brain regions: hypothalamus, hippocampus, stria- 
tum, frontal cortex, thalamus, and midbrain. The hypo- 
thalami were frozen for subsequent RIA measurement of 
B-END. Tissue samples from all animals of the same 
group were pooled for homogenization and subsequent 
opiate receptor assays. Some animals were perfused and 
their brains removed for immunohistochemical venfica- 
tion of the destruction of B-END cell bodies. 
Opiate receptor binding assays were done on each 
brain region of MSG-lesioned and control animals simul- 
taneously with both [3H]morphine (Amersham) and 
TABLE 1. Scutchurd plot summary for 13H]morphine binding 
~ ~ ~ 
K D  Bill,, 
(PM) r" 
Control MSG Control MSG Control MSG 
Striatum 1.2 0.9 240 267b 0.96 0.96 
Midbrain 2.3 2.6 242 257 0.97 0.99 
Cortex 1.4 1.7 162 182 0.98 0.95 
Hippocampus 1.3 1 . 1  114 101 0.97 0.95 
Thalamus 1 0.5 0.8 51 53 0.87 0.95 
Thalamus 2 1.2 1.8 102 99 0.73 0.83 
" Correlation coefficient of the regression line by computer analysis. 
p < 0.05 by multiple linear regression analysis. 
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TABLE 2. Scatchard plot summary for ['HIDADL enkephulin binding 
~~ 
K U  Bm,, 
(PM) r 
Control MSG Control MSG Control MSG 
Striaturn 6.7 4.2 500 408 0.99 0.95 
Midbrain 14.3 14.2 42 1 43 1 0.99 0.99 
Cortex 4.3 6.7 317 459 0.90 0.97 
Hippocampus 7.5 7.4 294 265 0.97 0.94 
Thalamus 1 9.9 8.8 135 227" 0.95 0.97 
Thalamus 2 2.7 1.7 39 82 0.80 0.80 
p < 0.05 by multiple linear regression analysis 
["IDADL enkephalin (Amersham). The assays were per- 
formed using a modification of opiate receptor binding 
assay of Akil et al. Each group contained seven animals. 
The tissues were homogenized at a concentration of 
50 mg/ml in 0.05 M Tris-HCI buffer, pH 7.4, (at 25OC) with 
5% dimethylsulfoxide (DMSO) to minimize freezing ef- 
fects. Previous studies in our laboratory have demon- 
strated no differential changes in either K D  or B,,, of mu, 
delta, or kappa receptors induced by DMSO or freezing. 
In addition, both MSG and control brain tissues were 
treated identically in this procedure. The brain homoge- 
nates were frozen at -70°C until use. Frozen homoge- 
nates were placed directly into a 37°C water bath and in- 
cubated for 45 min to promote dissociation of any 
endogenous ligands from the receptors. The tissues were 
centrifuged at 30,000 x g for 20 min, then resuspended in 
cold 0.05 M Tris buffer at a concentration of 50 mg tis- 
sue/ml buffer. This procedure removes the DMSO added 
prior to freezing. Aliquots of tissue (0.3 ml) were incu- 
bated with ["IDADL and [3Hlmorphine at concentra- 
tions ranging from 0.5 to 25 nM in a total assay volume of 
0.5 ml. All concentrations were run in triplicate. One mi- 
50 100 150 200 
p Molar 
FIG. 1. Scatchard plot for [3H]rnorphine in the thalamus. Con- 
trol rats: K, = 0.5 ? 0.25; B,,, = 51 f 22; MSG rats: K, = 
0.8 * 0.3; B,,, = 53 ? 16. B/F, bound/free. 
cromolar morphine and 1 ph4 DADL enkephalin were 
used to define nonspecific binding for [3H]morphine and 
[3H]DADL enkephalin, respectively. A mixture of 3H-lig- 
and and unlabeled ligand was used to calculate bound and 
free concentrations at higher concentrations of morphine 
and DADL enkephalin. In addition, samples were incu- 
bated with varying unlabeled concentrations of morphine 
with [3H]DADL enkephalin and DADL enkephalin with 
[3H]morphine to determine ICs0 for both ligands against 
both 3H-ligands. Samples were incubated at 4°C for 2 h. 
After incubation, samples were rapidly filtered under 
vacuum using Whatman GF/B glass fiber filters. The fil- 
ters were washed twice with 4.5 ml of cold Tris buffer and 
dispersed by shaking in 10 ml of Beckman aqueous scin- 
tillation cocktail and counted in a Beckman LS9000 liquid 
scintillation counter. Aliquots of the crude membrane 
preparation were assayed using the Biorad protein assays 
to ascertain that any differences between MSG and con- 
trol were not due to any dilutional error or differences in 
\ 
\ 
50 100 150 200 250 
p M o l a r  
FIG. 2. Scatchard plot for [3H]DADL enkephalin in thalamus. 
Control rats: K, = 9.9 rt 2.2, B,,, = 135 ? 34; MSG rats: K, = 
8.8 & 2.0, B,,, = 227 ? 59. BIF, bound/free. 
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p M o l o r  
FIG. 3. Scatchard plot for [3H]morphine in striatum. Control 
rats: K, = 1.2 f 0.25, B,,, = 240 2 44; MSG rats: K ,  = 0.9 f 
0.2, B,,, = 267 r 54. BIF, boundlfree. 
protein concentrations between groups subsequent to 
MSG treatment. A given brain region was completely 
studied in one experiment, simultaneously, to generate 
the data for comparison of MSG and controls in the Scat- 
chard analyses and the cross-competition paradigms. 
Dissociation constants (K,)  and receptor concentration 
(BmaX) were obtained from Scatchard plot analysis of the 
data for each ligand in each brain region using computer 
generated multiple linear regression analysis. 
RESULTS 
Immunohistochemical verification of selected 
MSG-lesioned versus control animals showed a 
consistent loss of B-END, immunolabeled in the ar- 
cuate of MSG-treated animals as compared with the 
matched controls. Biochemical measuring of B- 
END and alpha-melanotropin stimulating hormone 
(a-MSH) immunoreactivity in the hypothalamus of 
the MSG and controls showed >70?6 depletion of 
immunoreactivity of both a-MSH and B-END in 
MSG versus controls (Akil et al., in preparation). 
The binding results are summarized in Tables 1-4. 
The Scatchard plot data for morphine and DADL 
enkephalin from the first group of animals (Tables 1 
and 2) shows little if any change in the K o  between 
p Molar 
FIG. 4. Scatchard plot for [3H]morphine in cortex. Control 
rats: K, = 1.4 t 0.5, B,,, = 162 * 58; MSG rats: K, = 1.7 2 
0.6, 5,, = 182 2 65. BIF, boundlfree. 
MSG-treated and control groups. However, there 
are changes in the B,,, in two brain regions, the 
thalamus and striatum (Figs. 1-3). In the case of the 
striatum, the increase in mu receptors is not accom- 
panied by any changes in delta receptors. Owing to 
08r 
c1 Control K~:6.'7t1.4 
p M o l a r  
FIG. 5. Scatchard plot for [3H]DADL enkephalin in cortex. 
Control rats: K, = 4.3 f. 0.5, B,,, = 317 & 64; MSG rats: K, = 
6.7 f 1.4, B,, = 459 * 93. 
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TABLE 3. Thalamus IC,, (nM) in cross-competition 
IC,, vs. [3H]DADL enk. 
[3H]DADL enkepalin IC,, vs. [3H]morphine 
Control MSG Control MSG Control MSG 
1.6 19 
0.57 0.69 
Morphine (a) 1 .1  1.5 2.9 54 
(b) 1.5 2.2 2.2 15 
DADL (a) 24 37 18 15 
enkephalin (b) 32 28 13 25 
(a), experiment 1; (b), experiment 2. 
the limited amount of striatal tissue available, we 
were unable to replicate this study or employ the 
cross-competition paradigm described above. Thus, 
this may represent a random chance occurrence or 
it may be a real change. In the case of the thalamus, 
the number of delta receptors increased in the 
MSG-lesioned rats. This could be seen in the first 
group of MSG rats (9 months old, Thalamus 1) dis- 
played in Tables 1 and 2 and was replicated in the 
7-month-old MSG rats (Thalamus 2). In contrast, 
regions such as cortex show no changes in Scat- 
chard plot between MSG-treated and control rats 
(Figs. 4 and 5).  The cross-competition experiments 
further illustrate this point (Tables 3 and 4). Mor- 
phine, which ordinarily is more potent in displacing 
["HIDADL than DADL enkephalin, suddenly loses 
much of its potency (Figs. 6 and 7). Thus the ICsO of 
morphine changes from 3 to 54 nM. Since thalamus 
is a mu-rich area, this loss of potency demonstrates 
an increase in delta receptors, so that the pattern of 
ICs0 displacement resembles striatum or cortex 
(Table 4) (Figs. 7-9) more than it does thalamus. 
This loss of potency of morphine against DADL en- 
kephalin is shown again in the second set of experi- 
ments in which the ICS0 of morphine shifted from 
2 nM in the control animals to 15 nM in the MSG- 
lesioned animals. 
DISCUSSION 
The existence of mu and delta receptors as sepa- 
rate receptor subtypes is still controversial. Recent 
reports on naloxazone, an irreversible antagonist 
that blocks the binding of both mu and delta ligands, 
suggest that mu and delta may not be as clearly sep- 
arated as previously believed. However, cross-pro- 
tection studies by Robson and Kosterlitz (1979) and 
studies on selective inhibition of binding with alco- 
hol by Hiller et al. (1981) support different receptor 
subtypes. This demonstration of differential regula- 
tion of mu and delta receptors by neonatal MSG 
treatment lends further credence to the existence of 
subtypes of receptors and to the mu and delta re- 
ceptor paradigm. 
The common ligands utilized in multiple opiate 
receptor binding paradigms, e.g., morphine or dihy- 
dromorphine for mu receptors and DADL enkepha- 
lin for delta receptors, are not completely specific. 
Even at low concentrations, some delta receptors 
will be labeled by morphine and some mu receptors 
by DADL enkephalin. The lack of selectivity is af- 
fected by the relative number of the opiate receptor 
subtypes intrinsic to each brain. In the case of delta- 
poor receptor areas like midbrain, DADL enkepha- 
lin will label relatively more mu sites than in a delta- 
rich area like striatum or cortex. This is reflected in 
the relative ICS0 values in these regions. In the thal- 
amus of the control group, the ratio of mor- 
phine vs T3H]DADL : ICBO of morphine vs [3H]mor- 
phine) is 1.8 to 2, indicating a predominance of mu 
receptors. For MSG-treated rats this ratio became 
36 (54A.5) in experiment 1 and 7 (1Y2.2) in experi- 
ment 2. This change in index supports the Scatchard 
TABLE 4. Cortex IC,, (nM) in cross-competition 
IC,, vs. rH]DADL enk. 
[3H]Morphine [3H]DADL enkepalin IC,, vs. [3H]morphine 
Control MSG Control MSG Control MSG 
69 47 Morphine (a) 0.6 0.9 62 48 (b) 3.5 3 125 125 
DADL (a) 19 23 7.0 7.0 0.41 0.25 enkephalin (b) 20 28 9.5 5.4 
(a), experiment 1; (b), experiment 2. 
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FIG. 6. IC, curve for unlabeled morphine against YHImor- 
phine and r3H]DADL enkephalin in control rats in cortex. 
plot data showing a twofold increase in the B,,, of 
DADL enkephalin in the thalamus of MSG-treated 
rats, with no change in theB,,, of morphine binding. 
This demonstration of increases in delta recep- 
tors in the thalamus is selective among brain re- 
gions. Opiate receptor up- or down-regulation has 
been difficult to demonstrate using receptor binding 
paradigms despite the clear behavioral changes, 
such as the development of tolerance to opiates in 
behavioral paradigms. Previous attempts generally 




FIG. 8. ICS0 curve for unlabeled morphine against [3H]mor- 
phine and [3H]DADL enkephalin in control rats in thalamus. 
often a mu receptor agonist such as morphine, dihy- 
dromorphine, or etorphine. Few studies have exam- 
ined brain regions rather than whole brain. This 
demonstration of selective increase would not have 
been apparent in a whole brain preparation if only 
mu receptor ligands were used. The thalamus is a 
likely area for a receptor change to occur after a 
MSG lesion, since it is one of the primary terminal 
regions of the B-END fibers. Whether this binding 
change leads to a functional or behavioral change in 
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FIG. 7. IC, curve for unlabeled morphine against [3H]mor- 
phine and [3H]DADL enkephalin in MSG-treated rats in cor- 
tex. 
IH DADL 
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FIG. 9. IC, curve for unlabeled morphine against [3H]mor- 
phine and [3H]DADL enkephalin in MSG-treated rats in thala- 
mus. Note the similarity of this curve to IC, curves in cortex, 
a delta receptor-rich area. 
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supersensitivity to delta ligands) remains to be de- 
termined. 
This report of the alteration of one subtype of re- 
ceptor also has implications for the multiple opiate 
receptor theory. Although the existence of subtypes 
was postulated in 1975, the hypothesis has not been 
entirely accepted. The differential alteration of 
delta receptors with no changes in mu provides sub- 
stantial support that these are indeed functionally 
separable receptors. In the case of the thalamus the 
alteration in number of one receptor subtype with- 
out change in the other receptor implies a separate 
feedback system. Our data do not address the issue 
of whether the opiate receptor is a single macro- 
molecule with interconverting forms or distinct 
macromolecules. What we can conclude, however, 
is that even if the forms are indeed interconverting, 
each form can be regulated separately, and an in- 
crease in one (e.g., delta in thalamus) is not auto- 
matically accompanied by an increase or decrease 
in the other. 
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